The enzyme replacement therapy is designed to target the key mannose-6-phosphate receptor pathway
The enzyme replacement therapy is designed to target the key mannose-6-phosphate receptor pathway
High levels of skin clearance achieved for moderate to severe plaque psoriasis patients
Approval based on DAPA-CKD Phase III data
The finalists have been confirmed for the 2021 Clinical Researcher of the Year – The Americas competition.
Acquisition strengthens Bayer’s drug discovery capabilities
Libtayo plus platinum-doublet chemotherapy led to a 29% reduction in risk of death compared to chemotherapy alone
Planned Phase II study to combine the BET inhibitor with momelotinib
UK Competition and Markets Authority provisionally finds drug companies broke competition law
Drug resistant E. coli infections were not halted by reduction, according to new report
Agreement will support use of the ‘best evidence-based healthcare’ in the NHS
Neutralising antibody titers were observed in 98.5% of subjects
Vaccine side effects rare and outweighed by the benefits
Phase III trials did not demonstrate sufficient clinical benefit.
Less than one in 20 children had symptoms for more than four weeks
Sativex is a complex botanical formulation that contains the principal cannabinoids THC and CBD